246 related articles for article (PubMed ID: 19293768)
1. The evolving role of PET-CT in the management of esophageal cancer.
Chuang HH; Macapinlac HA
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):201-9. PubMed ID: 19293768
[TBL] [Abstract][Full Text] [Related]
2. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.
Pfau PR; Perlman SB; Stanko P; Frick TJ; Gopal DV; Said A; Zhang Z; Weigel T
Gastrointest Endosc; 2007 Mar; 65(3):377-84. PubMed ID: 17321235
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
4. The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response.
Erasmus JJ; Munden RF
Semin Radiat Oncol; 2007 Jan; 17(1):29-37. PubMed ID: 17185195
[TBL] [Abstract][Full Text] [Related]
5. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
7. Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
Salavati A; Basu S; Heidari P; Alavi A
Nucl Med Commun; 2009 Feb; 30(2):95-116. PubMed ID: 19194210
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
9. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer therapy: the role of PET-CT in decision making.
Pons F; Duch J; Fuster D
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):210-23. PubMed ID: 19293769
[TBL] [Abstract][Full Text] [Related]
11. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases.
Bruzzi JF; Truong MT; Macapinlac H; Munden RF; Erasmus JJ
Curr Probl Diagn Radiol; 2007; 36(1):21-9. PubMed ID: 17198889
[TBL] [Abstract][Full Text] [Related]
12. PET/CT of esophageal cancer: its role in clinical management.
Bruzzi JF; Munden RF; Truong MT; Marom EM; Sabloff BS; Gladish GW; Iyer RB; Pan TS; Macapinlac HA; Erasmus JJ
Radiographics; 2007; 27(6):1635-52. PubMed ID: 18025508
[TBL] [Abstract][Full Text] [Related]
13. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy.
Kim TJ; Kim HY; Lee KW; Kim MS
Radiographics; 2009; 29(2):403-21. PubMed ID: 19325056
[TBL] [Abstract][Full Text] [Related]
14. [Clinical utility of PET-CT for esophageal cancer].
Fujiwara Y; Kaibe N; Matsumoto T; Yamashita H; Koishi K; Kikuchi S; Sasako M; Kawata S; Oku N; Kashiwagi T
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2508-15. PubMed ID: 20009448
[TBL] [Abstract][Full Text] [Related]
15. Staging and treatment of advanced esophageal cancer.
von Rahden BH; Stein HJ
Curr Opin Gastroenterol; 2005 Jul; 21(4):472-7. PubMed ID: 15930991
[TBL] [Abstract][Full Text] [Related]
16. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy.
Munden RF; Macapinlac HA; Erasmus JJ
J Thorac Imaging; 2006 May; 21(2):137-45. PubMed ID: 16770230
[TBL] [Abstract][Full Text] [Related]
17. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
[TBL] [Abstract][Full Text] [Related]
19. Staging and restaging of advanced esophageal cancer.
Jamil LH; Gill KR; Wallace MB
Curr Opin Gastroenterol; 2008 Jul; 24(4):530-4. PubMed ID: 18622171
[TBL] [Abstract][Full Text] [Related]
20. [Current status of initial staging and posttreatment response evaluation in esophageal carcinoma].
Yasuda T; Imamoto H; Shiozaki H
Nihon Geka Gakkai Zasshi; 2008 Jan; 109(1):3-9. PubMed ID: 18320803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
